Intellia Therapeutics is trading 5% down at $11.48 as broader risk-off selling pressured growth-oriented and biotechnology stocks on August 18, 2026.
- The Nasdaq Composite fell 1.29%, while the S&P 500 declined 0.56%.
- Rising Treasury yields, geopolitical uncertainty, and higher oil prices further weighed on risk appetite.
- No company-specific announcement was identified.